This is the case with different types of cancer biomarkers including prostate-specific antigen (PSA), which presents a clinical threshold of 4 ng/ml for biopsy [9] and 0.4 ng/ml for monitoring cancer recurrence after radical prostatectomy [10–14]. This evidence concerns the gene KLK3 and cancer.